A bipartisan bill, recently introduced in the House of Representatives, would help to combat the abuse of over-the-counter cough medicine among teenagers.
A bipartisan bill, recently introduced in the House of Representatives, would help to combat the abuse of over-the-counter cough medicine among teenagers.
The “Preventing Abuse of Cough Treatments Act of 2014,” also known as the “PACT Act,” would restrict the sale of OTC cough medicine containing dextromethorphan (DXM) to adults aged 18 years and older and require a prescription for individuals younger than aged 18 years. In addition, the legislation requires that only legitimate entities can purchase bulk DXM and they will have to register with FDA or state agencies.
“Million of Americans use these cold medicines responsibly to gain relief from coughs and colds. However, these medicines are available at every supermarket, drugstore, and convenience store in the country giving teenagers access to purchase and abuse them,” said Rep. Bruce Braley (D-IA), who introduced the legislation with Rep. Bill Johnson (R-OH) at the end of January.
“As a parent, I’m always focused on what we can do to protect Iowa’s children – and after researching this issue, it became clear that something needed to be done,” Braley said in a press release.
DXM abuse among teens has been reported in 2013 at a rate of 1 in 20 teens in grades 8 through 12, according to the National Institute on Drug Abuse. In Iowa, one in 20 teens have abused OTC medicines, according to Bradley.
The PACT ACT is the House companion legislation to the Senate’s bill that was introduced by Sens. Bob Casey (D-PA) and Lisa Murkowski (R-AK) last March.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More